These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38455850)

  • 1. Beneficial Effects of Ursodeoxycholic Acid on Metabolic Parameters and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind, Placebo-Controlled Clinical Study.
    Lakić B; Škrbić R; Uletilović S; Mandić-Kovačević N; Grabež M; Šarić MP; Stojiljković MP; Soldatović I; Janjetović Z; Stokanović A; Stojaković N; Mikov M
    J Diabetes Res; 2024; 2024():4187796. PubMed ID: 38455850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomized, double-blind, placebo-controlled trial of polyphenols on the outcomes of inflammatory factors and oxidative stress in patients with type 2 diabetes mellitus.
    Grabež M; Škrbić R; Stojiljković MP; Vučić V; Rudić Grujić V; Jakovljević V; Djuric DM; Suručić R; Šavikin K; Bigović D; Vasiljević N
    Rev Cardiovasc Med; 2022 Feb; 23(2):57. PubMed ID: 35229548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
    Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
    Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic Acid Use After Bariatric Surgery: Effects on Metabolic and Inflammatory Blood Markers.
    Guman MSS; Haal S; Acherman YIZ; van de Laar AWL; Nieuwdorp M; Voermans RP; Gerdes VEA
    Obes Surg; 2023 Jun; 33(6):1773-1781. PubMed ID: 37186289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.
    Parés A; Caballería L; Rodés J; Bruguera M; Rodrigo L; García-Plaza A; Berenguer J; Rodríguez-Martínez D; Mercader J; Velicia R
    J Hepatol; 2000 Apr; 32(4):561-6. PubMed ID: 10782903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Ursodeoxycholic Acid for the Prevention of Gallstone Formation After Gastrectomy in Patients With Gastric Cancer: The PEGASUS-D Randomized Clinical Trial.
    Lee SH; Jang DK; Yoo MW; Hwang SH; Ryu SY; Kwon OK; Hur H; Man Yoon H; Eom BW; Ahn HS; Son T; Song KY; Lee HH; Choi MG; An JY; Lee SI; Lee KH; Ahn S; Park YS; Park DJ;
    JAMA Surg; 2020 Aug; 155(8):703-711. PubMed ID: 32584935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.
    Almasio PL; Floreani A; Chiaramonte M; Provenzano G; Battezzati P; Crosignani A; Podda M; Todros L; Rosina F; Saccoccio G; Manenti F; Ballardini G; Bianchi FP; Scheuer PJ; Davies SE; Craxì A
    Aliment Pharmacol Ther; 2000 Dec; 14(12):1645-52. PubMed ID: 11121914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
    Leuschner M; Maier KP; Schlichting J; Strahl S; Herrmann G; Dahm HH; Ackermann H; Happ J; Leuschner U
    Gastroenterology; 1999 Oct; 117(4):918-25. PubMed ID: 10500075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial.
    von Haehling S; Schefold JC; Jankowska EA; Springer J; Vazir A; Kalra PR; Sandek A; Fauler G; Stojakovic T; Trauner M; Ponikowski P; Volk HD; Doehner W; Coats AJ; Poole-Wilson PA; Anker SD
    J Am Coll Cardiol; 2012 Feb; 59(6):585-92. PubMed ID: 22300693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
    Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
    J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
    Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
    Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up.
    Hwang SJ; Chan CY; Lee SD; Wu JC; Tsay SH; Lo KJ
    J Gastroenterol Hepatol; 1993; 8(3):217-23. PubMed ID: 8100153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Possibilities for the use of ursodeoxycholic acid in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease].
    Rasskazova MA; Vorobyev SV; Butova HN
    Ter Arkh; 2023 May; 95(4):316-321. PubMed ID: 38158979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
    Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-centered trial investigating gestational treatment with ursodeoxycholic acid compared to metformin to reduce effects of diabetes mellitus (GUARD): a randomized controlled trial protocol.
    Lovell H; Mitchell A; Ovadia C; Pitrelli N; Briley A; Singh C; Marschall HU; Cruickshank K; Murphy H; Seed P; Williamson C
    Trials; 2022 Jul; 23(1):571. PubMed ID: 35854327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.
    Poupon RE; Eschwège E; Poupon R
    J Hepatol; 1990 Jul; 11(1):16-21. PubMed ID: 1975819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid increased bile flow and affects bile composition in the early postoperative phase following liver transplantation.
    Söderdahl G; Nowak G; Duraj F; Wang FH; Einarsson C; Ericzon BG
    Transpl Int; 1998; 11 Suppl 1():S231-8. PubMed ID: 9664985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial).
    Boerlage TCC; Haal S; Maurits de Brauw L; Acherman YIZ; Bruin S; van de Laar AWJM; Moes DE; van Wagensveld BA; de Vries CEE; van Veen R; Schouten R; Dijkgraaf MG; Fockens P; Gerdes VEA; Voermans RP
    BMC Gastroenterol; 2017 Dec; 17(1):164. PubMed ID: 29262795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid.
    Hess LM; Krutzsch MF; Guillen J; Chow HH; Einspahr J; Batta AK; Salen G; Reid ME; Earnest DL; Alberts DS
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):861-7. PubMed ID: 15159320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ursodeoxycholic acid on liver regeneration capacity after living donor hepatectomy: a prospective, randomized, double-blind clinical trial.
    Aloun A; Akbulut S; Garzali IU; Gonultas F; Baskiran A; Hargura AS; Colak C; Yilmaz S
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):999-1006. PubMed ID: 36808345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.